Overview
Over the past six months, the US Food and Drug Administration (FDA) has pursued a dual regulatory agenda: expanding flexibility to accelerate development and access while sharpening expectations around evidence generation, quality systems, and post‑market accountability. Recent guidance, pilot programs, and enforcement signals reflect an agency willing to adapt its frameworks, but also one that is increasingly focused on how sponsors generate, validate, and sustain evidence across the product life cycle. Below, we highlight key FDA developments from the past six months and their implications for the industry.
In Depth
Accelerated access, with increased focus on evidence planning
In April 2026, the FDA and the Centers for Medicare & Medicaid Services (CMS) announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a new initiative intended to expedite Medicare access for certain FDA designated Class II and Class III breakthrough devices. RAPID formalizes early and coordinated engagement between FDA, CMS, and device manufacturers so that evidence generated for FDA pre-market review can also support Medicare coverage determinations. By aligning regulatory and coverage expectations earlier in the development life cycle, particularly around clinical outcomes relevant to Medicare beneficiaries, the pathway is designed to reduce delays that have historically occurred between FDA market authorization and national Medicare coverage decisions.
Related FDA pilot programs, including the Technology-Enabled Meaningful Patient Outcomes (TEMPO) program, further reflect the agency’s effort to integrate regulatory oversight and coverage models earlier in the product life cycle. TEMPO introduces a risk‑based enforcement approach for certain digital health devices addressing cardio‑kidney‑metabolic, musculoskeletal, and behavioral health conditions, allowing manufacturers to deploy products under FDA enforcement discretion while collecting real‑world data to inform future regulatory decisions. Together, these initiatives underscore FDA’s focus on earlier coordination and predictability while reinforcing that accelerated access depends on well aligned evidence generation and operational readiness.
Modernizing evidence standards for precision and individualized therapies
In early 2026, the FDA released draft guidance outlining a new “plausible mechanism framework” for certain individualized and precision therapies, particularly those targeting rare and ultra rare diseases where traditional randomized controlled trials may be infeasible. The framework would not create a new approval pathway but would permit sponsors, in limited circumstances, to establish substantial evidence of effectiveness through focused clinical investigations supported by mechanistic data, natural history evidence, and confirmatory findings. While the draft guidance signals increased openness to flexible trial designs and nontraditional endpoints, the FDA emphasized that statutory approval standards remain unchanged and that flexibility at the pre approval stage would be paired with robust post approval obligations, including ongoing monitoring, transparency, and life cycle evidence generation.
This approach is consistent with other FDA actions in Q1 2026 aimed at modernizing evidence development in small or complex patient populations. In January 2026, the agency issued draft guidance endorsing broader use of Bayesian statistical methods and adaptive trial designs, including the use of prior data, external controls, and iterative analyses to support primary inference. Building on that foundation, in Q2, the FDA announced steps to support real time clinical trial models, including the launch of proof of concept trials that transmit safety signals and endpoint data to the agency on a continuous basis.
Renewed emphasis on quality systems and compliance
Manufacturing quality and inspection readiness remain a focal point of FDA activity. In March 2026, the FDA issued updated guidance on Form 483 responses, emphasizing timely engagement by senior management, comprehensive root cause analysis, and durable remediation rather than narrow corrective actions. Around the same time, the FDA launched the PreCheck pilot program, which allows earlier FDA engagement during pharmaceutical facility development and reflects a broader effort to strengthen supply chain resilience and improve predictability around manufacturing readiness.
The FDA also underscored expectations regarding clinical trial transparency. In April 2026, the agency publicly reminded more than 2,200 sponsors and researchers of their obligations to post trial results to ClinicalTrials.gov and indicated that continued noncompliance could prompt enforcement action.
Enforcement signals in high growth therapeutic areas
FDA leadership statements and enforcement announcements over the past six months reflect increased attention to areas experiencing rapid commercialization, particularly glucagon-like peptide-1 (GLP‑1) drugs. The agency has emphasized scrutiny of compounded GLP‑1 products, importation practices, and promotional claims, especially where marketing extends beyond approved labeling or relies on unsupported efficacy assertions.
For example, the FDA issued warning letters to telehealth companies and compounders for promoting compounded GLP‑1 products using marketing claims that suggest FDA approval, guaranteed effectiveness, or equivalence to FDA‑approved drugs.
Regulatory flexibility for artificial intelligence (AI), digital health, and wearables
The FDA continues to update its oversight framework for AI enabled technologies, software as a medical device, and wearable devices. In January 2026, for example, the agency revised guidance on clinical decision support software and non invasive wearable monitoring products to allow a broader set of lower risk technologies to reach market without premarket review, provided they meet defined criteria.
Other notable developments
- Expanded use of incentive based review programs: The FDA continues to rely on priority vouchers and expedited pathways for drugs and devices addressing serious and rare conditions.
- Reduced reliance on animal testing: The agency reported ongoing progress toward accepting alternative preclinical methods where adequately validated.
- Ongoing refinement of genome editing and gene therapy oversight: Through draft guidance and public statements, the FDA continues to refine safety and development expectations in this evolving area.
- Targeted industry communications: The FDA is increasingly relying on focused announcements and letters to highlight emerging safety, quality, and compliance risks rather than just broad rulemaking.